Clinical trial · Interventional
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
| Physical Inactivity | — | UNRESOLVED | — |
| Sarcopenia | — | UNRESOLVED | — |
| Toxicity Due to Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sarcopenia diagnostic test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Interventionnal
- description
- "Hand Grip" Dynamometer Chair rise test measurement of impedance SEFI Nutritional Intake Assessment Questionnaire GPAQ questionnaire SARC-F questionnaire
- interventionNames
- Diagnostic Test: Sarcopenia diagnostic test
Primary outcomes (1)
- measure
- Event-free survival according to sarcopenic statut
- timeFrame
- Day 1 of the first treatment cycle to Day 1 of the second treatment cycle, approx. 4 weeks
- description
- Event-free survival will be defined as the time from the date of the experimental visit to the date of the first documented dose-limiting toxicity. Participants who will not experience an event as of the time of data cut-off (beginning of the second cycle of treatment) or who stopped study participation before the end of the follow-up, will be right-censored. The measure will be analyzed using a COX multivariate model with event incidence rate as dependant variable and the sarcopenia statut as independent variable.
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure
References
Publications (0)
Data not yet available